Syngene International Launches OEB-5 GMP Bioconjugation Suite to Accelerate ADC Development
核心洞察
Syngene International (搜索) has added an OEB-5 rated GMP bioconjugation suite at its Bengaluru facility to provide fully integrated antibody-drug conjugate services from discovery through manufacturing.
The new facility enables both monoclonal antibody production and GMP bioconjugation at a single site, aiming to significantly compress ADC development timelines and reduce supply chain complexity.
This expansion places Syngene among a select group of CDMOs offering complete end-to-end ADC capabilities, supporting the fastest-growing segment in oncology therapeutics.
Syngene International (搜索), a global contract research, development and manufacturing organisation (CRDMO), has announced the addition of a GMP bioconjugation suite at its commercial biologics facility, Unit 3, in Bengaluru. This strategic expansion positions the company among a select group of CDMOs offering fully integrated, end-to-end services for antibody-drug conjugates (搜索) (ADCs) from discovery through to GMP manufacturing.
Advanced Safety Standards for High-Potency Compounds
The new facility features an OEB-5 rating, indicating its capability to safely handle highly potent compounds. This safety classification is crucial for ADC development, as these targeted cancer (搜索) therapies combine monoclonal antibodies (搜索) with cytotoxic drugs that require specialized containment protocols.
The bioconjugation suite is designed to accelerate ADC development timelines by enabling both monoclonal antibody (mAb) production and GMP bioconjugation at a single site. This integrated approach complements Syngene's existing commercial capabilities in payload and linker manufacturing, creating a comprehensive ADC development ecosystem.
Addressing Industry Challenges
"The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays," said Alex Del Priore, Head – LM CDMO, Syngene International (搜索). "By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing."
The facility addresses a critical industry need by consolidating traditionally fragmented ADC development processes. The services are supported by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle.
Expanding Capabilities and Future Plans
Expected to become operational within the current financial year, the new conjugation facility will support a range of advanced conjugates and related modalities. Building on a decade of experience in ADC discovery and proven expertise in handling high-potency payloads, linkers, and mAbs across GMP-compliant facilities, Syngene is expanding its capabilities to support clinical programmes with plans to develop commercial-scale capabilities in the future.
The laboratories will offer process development, analytical characterisation, and scale-up for both early- and late-stage programmes. This addition strengthens Syngene's ability to support biotech and biopharma clients seeking science-driven partners for their ADC programmes, reinforcing the company's focus on operational excellence in ADCs, which represent one of the fastest-growing segments with a growing pipeline of molecules entering clinical development.